Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy

Robert E. Merritt, MD  
Reiko E. Yamada, BA  
Ronald G. Crystal, MD  
Robert J. Korst, MD

Objective: Tumors down-regulate major histocompatibility complex class I expression, escaping recognition by the cellular immune response. We hypothesized that augmentation of tumor cell class I expression by interferon-gamma would enhance the cellular antitumor immune response and cure rate of an active immunotherapy strategy.

Methods: B16.F10 tumor cells were exposed to interferon-gamma in culture, and class I expression was quantified using flow cytometry. Syngeneic mice bearing established tumors were injected with interferon-gamma (5000 U, intraperitoneal), and class I expression was assessed using immunohistochemistry. Tumor-specific cytotoxic T lymphocytes were induced in mice by an intratumoral injection of AdCD40L (5 × 10^10 particles), an adenovirus gene transfer vector-based immunotherapy strategy previously demonstrated to augment cellular antitumor immunity. A conjugate-formation assay and the enzyme-linked immunospot assay were used to evaluate the binding and activation of cytotoxic T lymphocytes, respectively. Interferon-gamma was administered to tumor-bearing mice concomitantly with intratumoral AdCD40L. End points measured included the frequencies of cytotoxic T lymphocytes using the enzyme-linked immunospot assay, tumor size, and mouse survival. The role of class I expression was further evaluated by monoclonal antibody blockade in both in vitro and in vivo experiments.

Results: B16.F10 cells exposed to interferon-gamma expressed significantly more class I, both in vitro and in vivo, and were able to bind to and activate cytotoxic T lymphocytes more efficiently than untreated cells. Cytotoxic T-lymphocyte frequencies, tumor regression, and the cure rate induced by AdCD40L were augmented by the addition of a single dose of interferon-gamma in tumor-bearing mice. These in vitro and in vivo effects of interferon-gamma were attenuated by class I monoclonal antibody blockade.

Conclusions: Up-regulation of class I expression using interferon-gamma enhances the cellular antitumor immune response and cure rate of AdCD40L, an active immunotherapy strategy. This approach may be useful for human tumors that lack class I expression.

The major histocompatibility complex (MHC) represents a collection of genes encoding proteins that are integral in distinguishing between self and nonself by the immune system. Class I MHC molecules are glycoproteins expressed ubiquitously by most nucleated cells and have been shown to be necessary for the presentation of antigens manufactured by these cells to naive CD8+ T lymphocytes. As such, class I molecules are thought to play a vital role in cell-mediated immunity against virally infected cells as well as tumors. One mechanism by which
tumor cells are thought to escape the antitumor immune response by attenuating their expression of MHC class I molecules. For example, class I is only inconsistently expressed by human lung cancer cells in vitro and in vivo.\textsuperscript{a,b,6}

Many agents, including some cytokines and chemotherapeutics, have been shown to enhance MHC class I expression by tumor cells.\textsuperscript{g,i} One of the most well-characterized modulators in this regard is interferon-gamma (IFN\textsubscript{G}), which has been shown to enhance class I expression in multiple human lung cancer cell lines.\textsuperscript{g,i} Despite this, a paucity of data exists concerning the modulation of class I molecule expression by IFN in established tumors in vivo. In our laboratory, we have developed active antitumor immunotherapy strategies that are dependent on the generation of tumor-specific, cellular immunity.\textsuperscript{11,12} One of these strategies has involved the transduction of established murine tumors with an adenovirus (Ad) gene transfer vector containing the gene for CD40 ligand (AdCD40L).\textsuperscript{11} However, these strategies have been clearly less effective in murine tumors with an adenovirus (Ad) gene transfer vector containing the gene for CD40 ligand (AdCD40L).\textsuperscript{11} However, these strategies have been clearly less effective in murine tumors that express low levels of MHC class I.\textsuperscript{g,i} Given that IFN\textsubscript{G} enhances the expression of class I by tumor cells in vitro,\textsuperscript{g,i} we hypothesized that administration of IFN\textsubscript{G} to mice bearing established tumors would up-regulate MHC class I expression by the tumors and, subsequently, enhance tumor-specific cellular immunity induced by AdCD40L. In this regard, the data show that (1) exposure of B16.F10 tumor cells to IFN\textsubscript{G} augments MHC class I expression in vitro and in vivo and enhances tumor cell binding to tumor-specific cytotoxic T lymphocytes (CTLs); (2) treatment of tumor-bearing mice with a single dose of IFN\textsubscript{G} results in more efficient generation of tumor-specific CTLs by an active immunotherapy strategy (AdCD40L); (3) exposure of B16.F10 tumor cells to IFN\textsubscript{G} enhances tumor-specific CTL activation in coculture; (4) a single dose of IFN\textsubscript{G} administered to tumor-bearing mice augments the antitumor activity and cure rate of an established immunotherapy strategy (AdCD40L); and (5) these synergistic effects of IFN\textsubscript{G} are attenuated by the administration of an anti-MHC class I monoclonal antibody (MAb).

Materials and Methods

Mice

Female wild-type C57BL/6 (H-2b) mice (6-8 weeks old) were obtained from Jackson Laboratories (Bar Harbor, Me). The mice were housed under specific pathogen-free conditions and treated according to the National Institutes of Health guidelines. All animal procedures were approved by the Institutional Animal Care and Use Committee.

Cell Culture

B16.F10 (H-2b) and Lewis Lung Carcinoma (LLC; H-2b) are syngeneic to C57BL/6 mice. The cell lines were obtained from American Type Culture Collection (ATCC, Manassas, Va; catalog no. CRL 6475) and maintained in complete Dulbecco’s modified Eagle’s medium (DMEM; 10% fetal bovine serum, 100 \textmu g/mL streptomycin, and 100 U/mL penicillin) at 5% CO\textsubscript{2} and 37°C.

Adenovirus Vectors

All gene transfer vectors used in this study are replication-deficient. E1-, E3-vectors based on the adenovirus serotype 5 (Ad5) genome. AdCD40L contains an expression cassette with the murine CD40L DNA under the control of the cytomegalovirus early-immediate promoter/enhancer.\textsuperscript{11} AdNull, a control vector, is similar to AdCD40L but contains an empty expression cassette.\textsuperscript{13} Adenovirus vectors were propagated in human embryonic kidney cells (293 cells; ATCC) and purified through 2 cesium chloride gradient ultracentrifugations as previously described.\textsuperscript{14,15} The viral particle concentration was determined by ultraviolet absorbance at 260 nm.\textsuperscript{16}

Quantification of MHC Class I Expression in Vitro

To determine whether IFN\textsubscript{G} up-regulates the expression of class I by B16.F10 cells in vitro, 50% confluent B16.F10 cells were exposed to 500 U/mL of recombinant murine IFN\textsubscript{G} (rmIFN\textsubscript{G}; Roche Diagnostics, Mannheim, Germany) for 48 hours in complete DMEM at 37°C. The cells were harvested, washed 3 times with phosphate-buffered saline (PBS), and stained with either fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse H-2Kb MAb or FITC-mouse immunoglobulin G (IgG)\textsubscript{2} isotype control antibody (Pharmingen, San Diego, Calif). The cells were then subjected to flow cytometric analysis (FACStar, Becton Dickinson, San Jose, Calif) to determine H-2Kb MHC class I expression.

Modulation of MHC Class I Expression in Vivo

To assess the ability of IFN\textsubscript{G} to enhance MHC class I expression by established tumors in vivo, 5 \times 10\textsuperscript{5} B16.F10 cells were injected subcutaneously in the right flanks of wild-type C57BL/6 mice. When the tumors were approximately 45 to 50 mm\textsuperscript{2} (day 8), a single subtherapeutic dose (5000 U) of rmIFN\textsubscript{G} was administered into the peritoneal cavity (IP). The animals were killed and the tumors harvested 24 or 48 hours after rmIFN\textsubscript{G} injection. Untreated tumor-bearing mice served as negative controls. The tumors were resected from the right flank, embedded in Optimal Cutting Temperature compound (Sakura Finetek, Torrance, Calif), snap-frozen in a 2-methylbutane/dry ice bath, and prepared as 10-\mu m frozen sections. The tumor sections were blocked with 5% goat serum (Sigma Chemical Co, St Louis, Mo) for 20 minutes, washed with PBS, and incubated with a biotin-conjugated mouse anti-mouse H-2Kb MAb (Pharmingen) for 2 hours. The slides were then washed with PBS and incubated with avidin-horseradish peroxidase solution (Pharmingen) for 30 minutes. After further washing with PBS, the tumor sections were exposed to 3,3’-diaminobenzidine chromagen substrate (Pharmingen) for 10 minutes, washed with PBS, and counterstained with hematoxylin. Following 3 washes with deionized water, the tumor sections were rehydrated with 95% ethanol and mounted for light microscopy.

Generation and Purification of Tumor-Specific Cytotoxic T Lymphocytes

To generate activated tumor-specific CD8+ CTLs, 5 \times 10\textsuperscript{5} B16.F10 cells were injected into the right flanks of C57BL/6 mice.
When the tumors reached 45 to 50 mm$^2$, AdCD40L (5 × 10$^{10}$ particle units in 100 μL PBS) was injected intratumorally. Seven days after AdCD40L administration, the mice were killed and their spleens were harvested. The spleens were minced with a razor and passed through a 100-μm nylon mesh filter. The resulting splenocyte suspensions were treated with ACK Lysing Buffer (Biosource International, Camarillo, Calif) to lyse red blood cells and washed with PBS. The Spinsep murine cell enrichment procedure (Stem Cell Technologies, Vancouver, BC, Canada) was then performed to purify CD8$^+$ T lymphocytes according to the manufacturer’s instructions. Flow cytometric analysis indicated that 90% of the purified splenocytes were CD8$^+$ T lymphocytes (data not shown).

**Cytotoxic T-Lymphocyte Binding Assay**

To assess the ability of CTLs to bind to target cells, a conjugate-formation binding assay was performed as described by Nakamura and colleagues$^{17}$ and Noguchi and colleagues.$^{18}$ B16.F10 cells were cultured in either complete DMEM or complete DMEM with the addition of 500 U/mL of rmIFN$\gamma$ for 48 hours. The cells were collected using trypsin-ethylenediaminetetraacetic acid and washed 3 times with PBS. The B16.F10 cells were stained with 1 μg/mL of hydroethidine (Molecular Probes, Junction City, Ore) for 1 hour at 37°C. The purified CD8$^+$ T lymphocytes from AdCD40L-treated mice were stained with 1 μg/mL of sulfofluoresceindiacetate (Molecular Probes) for 1 hour at 37°C. The stained CD8$^+$ T lymphocytes were then cocultured with either rmIFN$\gamma$-exposed B16.F10 cells or untreated B16.F10 cells at a 1:1 ratio (8 × 10$^5$ cells each) for 15 minutes at 37°C. Purified mouse anti-mouse H-2Kb MAb (4 μg; Pharmingen) was added to selected wells to assess the role of MHC class I in CTL binding. Binding of CD8$^+$ T lymphocytes and B16.F10 cells was then quantified using 2-color flow cytometry (FACStar; Becton Dickinson). The percentage of bound CD8$^+$ cells was calculated as follows: Binding (%) = (no. of green-red double positive counts)/(total no. of green positive counts) × 100.

**IFN$\gamma$ Enzyme-Linked Immunospot Assay**

To quantify the frequencies of tumor-specific CTLs, the enzyme-linked immunospot (ELISPOT) assay was employed. The ELISPOT assay is a sensitive and reproducible assay for the functional and quantitative determination of the proportion of tumor-specific CTLs$^{19,20}$ and has become a standard method for the determination of CTLs in immunotherapy clinical trials.$^{20}$ Each spot observed in the assay represents a single, tumor-specific, activated T lymphocyte, detected by its ability to secrete IFN$\gamma$.

**Target cell preparation.** Target cells consisted of B16.F10 cells exposed to rmIFN$\gamma$ (500 U/mL; 48 hours), untreated B16.F10 cells, or the syngeneic negative control cell line, LLC. Prior to their use in the ELISPOT assay, target cells were washed with PBS and treated with 100 μg/mL of mitomycin C (Sigma) at 37°C for 1 hour. The tumor cells were then washed in complete ELISPOT medium (RPMI 1640 supplemented with 10% fetal bovine serum, 100 μg/mL streptomycin, 100 μg/mL penicillin, 10 mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer, 1 mmol/L L-glutamine, and 5 × 10$^{-5}$ mol/L β-mercaptoethanol) and resuspended at 10$^6$ cells/mL.

**Effector cell preparation.** Effector cells for use in the ELISPOT assay were generated using the in vivo tumor model previously described (see Generation and Purification of Tumor-Specific Cytotoxic T Lymphocytes). Four groups of effector cells were prepared, which included total splenocytes from (1) AdCD40L-treated mice, (2) AdCD40L-treated mice that also received a concomitant IP injection of rmIFN$\gamma$ (5000 U), (3) AdNull-treated mice, and (4) PBS-treated mice. Unlike the preparation for the binding assay, CD8$^+$ T cells were not purified from total splenocytes for use in the ELISPOT assay, with the goal of preserving the presence of antigen-presenting cells. The splenocytes were resuspended in complete ELISPOT medium at a concentration of 8 × 10$^5$ cells/mL.

**ELISPOT assay.** Ninety-six-well multiscreen-IP membrane plates (Millipore, Bedford, Mass) were coated with 100 μL of a rat anti-mouse IFN$\gamma$ MAb (Mabtech, Cincinnati, Ohio) at a concentration of 10 μg/mL overnight at 4°C. The plates were blocked with 150 μL of complete ELISPOT medium and incubated for 2 hours at 37°C. The blocking buffer was decanted and 4 × 10$^5$ splenocytes/50 μL of complete ELISPOT medium were added to each well, followed by incubation for 2 hours at 37°C. Target cells (5 × 10$^4$ cells/50 μL of complete ELISPOT medium) were then added to each well and the plates were incubated for 20 hours at 37°C. After incubation, the plates were washed with PBS and 0.05% Tween 20 (Sigma). A biotinylated anti-rat IgG antibody (Mabtech) was diluted to 1 μg/mL in PBS/0.5% bovine serum albumin, and 100 μL was added to each well. The plates were incubated for 2 hours at 37°C and washed with PBS/0.05% Tween 20. After washing, 100 μL of avidin-enzyme complex (Vector Laboratories, Burlingame, Calif) was added to each well and incubated for 1 hour at room temperature. The plates were then washed and treated with 100 μL of 3-amino-9-ethy carbazole substrate (Sigma) and incubated for 4 minutes at room temperature, followed by rinsing with water to stop the reaction. The plates were then analyzed with the KS ELISPOT Automated Reader System (Carl Zeiss, Chester, Va).

**Evaluation of in Vivo MHC Class I Expression Modulation on the Antitumor Properties of AdCD40L**

B16.F10 tumor cells (5 × 10$^5$ cells in 100 μL of PBS) were injected into the right flanks of C57BL/6 mice. When the tumor growth reached 45 to 50 mm$^2$, treatment with PBS, AdNull, or AdCD40L (5 × 10$^{10}$ particles) was administered intratumorally in 100 μL of PBS. Additional mice received a single dose of IP rmIFN$\gamma$ alone (5000 U), with AdNull, or with AdCD40L. The size of the flank tumors was assessed every 2 to 3 days by measuring the largest perpendicular diameters using microcalipers and were recorded as an average tumor area (mm$^2$). When the animals appeared moribund or the tumor growth exceeded 15 mm in the largest diameter, the mice were killed and this time point was defined as date of death for survival analysis.

**Evaluation of MHC Class I Blockade with MHC Class I MAb in Vivo**

To assess the role of MHC class I expression enhancement by IFN$\gamma$ in vivo, tumor-bearing mice receiving intratumoral AdCD40L (5 × 10$^{10}$ particles) and IP IFN$\gamma$ (5000 U) were treated with 3 successive intratumoral injections of mouse anti-mouse H-2Kb MAb (20 μg/100 μL PBS; Sigma) on days 8 to 10 after tumor injection. Untreated mice and mice treated with AdCD40L
and IFNγ served as controls. The size of the flank tumors was assessed every 2 days by measuring the largest perpendicular diameters using microcalipers and were recorded as an average tumor area (mm²). A subset of mice from each group were killed 7 days after AdCD40L and IFNγ injection and the spleens were harvested. The frequencies of tumor-specific CTLs were then evaluated using the ELISPOT assay as previously described.

Statistical Analysis
All data are reported as the mean ± SEM unless otherwise specified. Statistical significance between means was determined using the unpaired, 2-tailed Student t test. Survival evaluation was performed using the Kaplan-Meier analysis (P values were determined by Breslow test for significance).

Results
Exposure of B16.F10 Cells to rmIFNγ Enhances MHC Class I Expression in Vitro
The effect of rmIFNγ on the expression of MHC class I was determined by incubating B16.F10 cells with 500 U/mL of rmIFNγ for 48 hours. B16.F10 cells exposed to 500 U/mL of rmIFNγ demonstrated significantly enhanced expression of MHC class I molecules compared with naive B16.F10 cells (Figure 1). Of the B16.F10 cells treated with rmIFNγ, 95% expressed MHC class I while naive B16.F10 cells did not show any detectable expression. B16.F10 cells exposed to rmIFNγ and stained with an isotype-matched control antibody did not demonstrate any detectable MHC class I expression (data not shown).

Treatment of B16.F10 Tumor-Bearing Mice with a Single Dose of rmIFNγ Enhances MHC Class I Expression in Vivo
To determine if rmIFNγ would enhance expression of MHC class I in established B16.F10 tumors in vivo, tumor-bearing mice were injected with a single IP dose of rmIFNγ (5000 U). The tumors from mice receiving rmIFNγ uniformly expressed the H-2Kb MHC class I antigen at both 24 and 48 hours following administration of the cytokine (Figure 2, A and B). B16.F10 tumors from untreated mice expressed low levels of H-2Kb MHC class I (Figure 2, C). There was also no detection of H-2Kb antigen in B16.F10 tumors that were stained with the isotype-matched control antibody (not shown).

Exposure of B16.F10 Tumor Cells to rmIFNγ Enhances Binding of CD8+ T Lymphocytes in Vitro
The conjugate-formation assay was performed to establish the effect of rmIFNγ on the ability of CD8+ CTLs to bind to tumor cells (a class I–mediated phenomenon). The CD8+ CTLs were able to bind B16.F10 cells more effectively if the tumor cells had been exposed to rmIFNγ (Figure 3, B and D) compared with untreated tumor cells (Figure 3, A and D; P = .002). Furthermore, the addition of an MAb that binds MHC class I to these reaction conditions clearly inhibited the binding of CTLs to target cells (Figure 3, C and D; P = .007, rmIFNγ-exposed cells incubated with H-2Kb MHC class I MAb vs rmIFNγ-exposed cells alone).

Prior Exposure of Target Tumor Cells to rmIFNγ in Culture Enhances Tumor-Specific Cytotoxic T-Lymphocyte Activation in Vitro
Because the class I–mediated binding of CTLs (effector cells) to tumor cells (target cells) results in activation of the bound T cells,21-23 we sought to determine whether the enhanced binding induced by rmIFNγ exposure between these cells would augment CTL activation. To accomplish this, splenocytes from B16.F10 tumor-bearing mice that received intratumoral PBS, AdNull, or AdCD40L were harvested and incubated in vitro with untreated B16.F10 cells, B16.F10 cells exposed to rmIFNγ, or LLC negative control cells for 20 hours in anti-IFNγ MAb-coated 96-well plates (ELISPOT assay). As an additional control, splenocytes were incubated in complete ELISPOT medium without tumor cells. When the effector cells (splenocytes) were obtained from AdCD40L-treated mice, previous exposure of the B16.F10 cells (target cells) to rmIFNγ resulted in significantly greater frequencies of activated CTLs compared with stimulation with B16.F10 cells that had not been exposed to this cytokine (Figure 4, A; P = .01). As expected, minimal CTL activation was observed when splenocytes were obtained from untreated tumor-bearing mice (Figure 4, B), mice that received AdNull (Figure 4, C), or
naive, tumor-free mice (Figure 4, D), regardless of the target cell type.

The Addition of a Single Dose of rmIFNγ to an Active Immunotherapy Strategy Enhances Cytotoxic T-Lymphocyte Generation in the Tumor-Bearing Host

Because MHC class I expression plays an integral role in the presentation of tumor antigens to naive T lymphocytes, we sought to determine whether up-regulating MHC class I expression by established tumors in vivo (using rmIFNγ) would result in enhanced generation of tumor-specific CTLs when combined with an active immunotherapy strategy. To investigate this, B16.F10 tumor-bearing mice were either treated with intratumoral AdCD40L or AdNull or left untreated. A similar experiment was simultaneously conducted with the same groups, except that a single IP dose of rmIFNγ was administered (5000 U). LLC cells served as control target cells. The relative frequency of CTLs was then assessed using the ELISPOT assay. Significantly greater frequencies of activated tumor-specific CTLs were obtained from the spleens of mice that had received both AdCD40L and rmIFNγ when compared with AdCD40L alone (Figure 5; P = .000004) or any other treatment group.

In addition, minimal CTL generation was observed in any group when LLC cells were used as targets (not shown).

The Addition of a Single Dose of rmIFNγ Enhances the Antitumor Activity and Cure Rate of AdCD40L

To determine whether the addition of a single dose of rmIFNγ would augment the antitumor properties of AdCD40L in vivo, B16.F10 tumor-bearing mice were given intratumoral AdCD40L as well as IP rmIFNγ (5000 U) concomitantly. Additional groups of mice were treated with intratumoral PBS, AdNull, AdNull with IP rmIFNγ, or IP rmIFNγ alone. Tumor regression was more pronounced in the mice receiving AdCD40L and rmIFNγ compared with mice receiving AdCD40L alone (Figure 6, A; P = .0004), AdNull (P = .001), rmIFNγ alone (P = .0004), AdNull with IFNγ (P = .001), or PBS (P = .000004). In addition, the cure rate observed with the combination of AdCD40L and rmIFNγ was superior to that of any other group (Figure 6, B; P = .01 vs AdCD40L alone; P = .008 vs AdNull; P = .0017 vs AdNull plus rmIFNγ; P = .0017 vs rmIFNγ alone; P = .0018 vs PBS).

Blockade of MHC Class I in Vivo Attenuates the Synergistic Effect of rmIFNγ on the Antitumor Activity and CTL Generation Induced by AdCD40L

To dissect the role of enhanced MHC class I expression in the synergistic effect of rmIFNγ on tumor regression and CTL generation induced by AdCD40L, 3 successive intratumoral injections of MHC class I MAb were administered. The extent of tumor regression was significantly greater in mice treated with AdCD40L and rmIFNγ compared with mice receiving AdCD40L, IFNγ, and MHC class I MAb (Figure 7, A; P = .007) or PBS alone (Figure 7, A; P = .00001). This effect persisted for 6 days after the initial intratumoral injection of MHC class I MAb, after which time regression rates became similar between the 2 groups receiving AdCD40L. In addition, the enhanced CTL generation afforded by rmIFNγ was significantly diminished in the animals that received MAb blockade (Figure 7, B; P = .016, AdCD40L, rmIFNγ vs AdCD40L, rmIFNγ plus anti-class I MAb). Finally, minimal stimulation was observed in any group when LLC cells were used as targets (not shown).
Lung cancer is responsible for more cancer deaths than any other malignant tumor in the United States. Fewer than 15% of patients presenting with lung cancer will ever be cured of their disease, with the vast majority of patients succumbing to distant metastasis, implying that more effective systemic therapy is a priority for these patients. Augmentation of antitumor immunity represents a treatment strategy that has the potential to be both tumor-specific as well as systemic in nature; however, reports describing its use for patients with lung cancer have not conclusively demonstrated efficacy. The antitumor immune response has traditionally been divided into afferent (stimulatory) and efferent (effector) limbs, with MHC class I molecules playing an integral role in both limbs. One mechanism by which tumor cells may evade the immune response is by down-regulating the expression of MHC class I on their surface, a process that could potentially interfere with both CTL generation (afferent limb) as well as subsequent recognition and binding of CTLs to target tumor cells (effector limb). This phenomenon is evident in human lung cancer cell lines, where as many as 33% to 43% have lost MHC class I expression. In our laboratory, which is focused on the use of gene transfer to induce antitumor immunity, we have observed that active immunotherapy strategies are significantly less effective in murine tumor models that express little or no MHC class I, exemplified by the metastatic variant of the B16 melanoma, B16.F10. Given this information, the purpose of the present study was to determine whether MHC class I expression could be en-

**Figure 3.** Up-regulation of H-2Kb MHC class I expression enhances the binding of CD8+ CTLs to B16.F10 tumor cells in a conjugate-formation assay. Naive B16.F10 cells or rmIFNγ-exposed B16.F10 cells were stained with hydroethidine (red), and tumor-specific CD8+ CTLs were stained with sulfofluoresceindiacetate (green). The 2 cell populations were then cocultured and subjected to 2-color flow cytometry. The binding of CD8+ CTLs and B16.F10 cells is defined as the double positive population in the right upper quadrant. A to C, Cytograms from a representative experiment of 3 independent experiments. A, Naive B16.F10 cells cocultured with CD8+ CTLs. B, rmIFNγ-exposed B16.F10 cells cocultured with CD8+ CTLs. C, rmIFNγ-exposed B16.F10 cells cocultured with CTLs and anti-MHC class I MAb. D, Summary data from 3 separate experiments performed. The % binding is defined as: Binding (%) = (no. of green-red double positive cells)/(no. of green positive cells) × 100. Each bar represents the mean ± SEM.
enhanced on B16.F10 cells and whether this up-regulation would result in (1) more efficient tumor-specific CTL generation in tumor-bearing mice (afferent limb) and (2) more efficient tumor cell–induced binding and activation of tumor-specific CTLs (efferent limb). The data show that MHC class I expression by B16.F10 cells is readily enhanced by exposure to the murine cytokine, rmIFNγ, in vitro and in vivo, and that this up-regulation results in more efficient binding of tumor-specific CTLs to B16.F10 cells. Furthermore, a single dose of rmIFNγ enhances the generation of CTLs by tumor-bearing mice (afferent limb) and augments the antitumor effect and cure rate observed with an established active immunotherapy strategy (AdCD40L). Finally, B16.F10 cells that have been exposed to rmIFNγ are more potent activators of CTLs than tumor cells that have been exposed to this cytokine.

Enhancement of the Afferent Limb of the Antitumor Immune Response by a Single Dose of rmIFNγ

The afferent limb of the antitumor immune response involves presentation of tumor-associated antigens to naive CD8+ T lymphocytes, a process that requires MHC class I expression by tumor cells.1-3 With the addition of costimu-
lation, these T cells are then able to differentiate into tumor-specific CTLs, proliferate, and circulate throughout the body. In this regard, AdCD40L is an adenovirus gene transfer vector encoding the murine CD40 ligand cDNA and has been demonstrated to augment the afferent limb of the antitumor immune response by generating tumor-specific CTLs when administered intratumorally in mice, resulting in regression of established tumors.11 Tumor regression and cure rates are limited, however, when this vector is used to treat murine tumors that express little or no MHC class I (eg, B16.F10).11 As a strategy to augment the antitumor effect of AdCD40L when used to treat MHC class I-deficient tumors, we sought to up-regulate MHC class I expression on established tumors in vivo using rmIFN/ H9253, a cytokine known to modulate MHC class I expression by many tumor cell types in vitro.8,10,26 Interestingly, only a single dose of systemic rmIFN/ was necessary to markedly enhance MHC class I expression by many tumor cell types in vitro.8,10,26

Enhancement of the Efferent Limb of the Antitumor Immune Response by a Single Subtherapeutic Dose of rmIFNγ

The efferent limb of the antitumor immune response is invoked when antigen-specific, differentiated CTLs reencounter tumor cells expressing the original tumor-associated antigens. The CTLs then bind to the tumor cell via interaction between MHC class I and the CD8+ T-cell receptor, resulting in activation of the CTL, cytokine release, and initiation of the apoptotic cascade in the bound tumor cell.1-3 Given the vital role of MHC class I in CTL binding and activation in the efferent limb, we sought to determine whether prior exposure of target tumor cells to rmIFNγ would make these processes more efficient based on the ability of this cytokine to up-regulate MHC class I expression. The present study suggests that this is true and is supported by the following observations. First, although CTLs from AdCD40L-treated mice bind target B16.F10 cells in vitro, this binding is significantly more pronounced if the tumor cells are pretreated with rmIFNγ. Second, this

A. Tumor Area

B. Survival

Figure 6. A single dose of rmIFNγ enhances the antitumor effect and cure rate obtained with intratumoral injection of AdCD40L. Twelve days after B16.F10 flank tumor initiation, C57BL/6 mice were randomized to 6 groups: AdCD40L plus IP rmIFNγ (n = 6); AdCD40L alone (n = 6); AdNull plus IP rmIFNγ (n = 6); AdNull alone (n = 5); IP rmIFNγ alone (n = 5); or PBS (n = 5). All vectors were administered intratumorally (5 × 1010 particle units/100 μL of PBS), and mIFNγ (5000 U) was administered concomitantly with the adenovirus vectors. The tumor area was assessed at 2- to 3-day intervals with micrometers. The data points represent the mean tumor area ± SEM. The mice were killed when the largest tumor diameter reached 15 mm. A, Tumor area. B, Survival. The arrows indicate the day of treatment.
enhanced binding induced by rmIFNγ is abrogated by the addition of an anti-MHC class I MAb to the reaction conditions. Finally, the proportion of tumor-specific CTLs that are activated by exposure to B16.F10 tumor cells in the ELISPOT assay is markedly increased by pretreatment of the tumor cells with rmIFNγ, confirming that the up-regulated MHC class I is indeed a functional receptor.

Clinical Implications of MHC Class I Expression Modulation

Given the relative lack of significant antitumor responses in clinical immunotherapy trials and the common observation that human tumors seem to down-regulate MHC class I expression to evade the immune response, enhancement of MHC class I expression to augment CTL generation represents a valid approach to enhance the antitumor immune response induced by clinical immunotherapeutic strategies. IFNγ is a reasonable agent to investigate in this regard because (1) its ability to enhance MHC class I expression in multiple tumor types in vitro is reasonably well characterized, (2) the data from the present study suggest that it may be used in this capacity at a low, subtherapeutic, nontoxic dose; and (3) its toxicity profile has already been elucidated in humans. Despite these advantages, some tumor cell lines are unresponsive to the class I-modulating properties of IFNγ. As a result, further investigation regarding both the mechanism of class I up-regulation, as well as other modulating agents, is warranted.

References

11. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo...


Discussion

**Dr Dao D. Nguyen (Bethesda, Md.).** How toxic is IFNγ injection to animals?

**Dr Merritt.** We gave a single intraperitoneal injection at the time that we gave an intratumoral injection of either AdCD40 ligand or the control vector.

**Dr Nguyen.** For future application, how do you envision using this strategy in human immunotherapy? I guess, and Dr Korst can correct me, if you’re planning to develop this treatment for lung cancer, for example, which is very poor at expressing MHC class I, how do you plan to up-regulate class I expression?

**Dr Merritt.** Well, in terms of toxicity, it’s already been worked out for IFNγ in previous studies treating human renal cell carcinoma. We would essentially give an intratumoral injection of the AdCD40 ligand and then give intravenous IFNγ at the time of therapy.

**Dr Nguyen.** Are you planning to use all the pharmacologics that might up-regulate for MHC class I? We have done that before using a drug like decitabine, which is a demethylating agent, and there is increase in expression of class I in the culture lung cancer cell lines. Do you have any plan of using all the strategies besides IFNγ used to up-regulate the MHC class I expression?

**Dr Merritt.** No. Initially we would start with giving intravenous IFNγ in combination with our adenoviral gene transfer vector to see if we could get efficacy. That would be the initial experiment.

**Dr Richard J. Battafarano (St Louis, Mo.).** It’s pretty clear that you need class I expression for your CTLs to lyse the tumor cells. But really, what your data shows is that you need class I expression to actually generate the immune response, I assume through your dendritic cells, because the CD40 ligand would enhance the dendritic cells. Why do you think class I expression is so important on the tumors at the time that you’re generating the immune response? It’s clear why it would be important at the time you’re trying to lyse the tumor cells. Why do you think class I expression is important then?

**Dr Merritt.** In previous studies where the AdCD40 ligand was used as a monotherapy, there was actually an antitumor response that was demonstrated in mirroring cell lines that were immunogenetic and that expressed MHC class I. And in the murine cancer lines that did not express class I, there was a less effective antitumor effect. We think that the IFNγ is augmenting the MHC class I up-regulated on the immunogenic cell lines, therefore making these cells more susceptible to CTL-mediated cell lysis.

**Dr Battafarano.** But do you think that there is something else being up-regulated, that there is some other tumor antigen that might be being up-regulated in there, and that’s really what the dendritic cells are processing?

**Dr Merritt.** Do you mean in terms of costimulatory molecules? It would be hard for us to ascertain that based on just this study alone. But it is a possibility.

**Dr Robert J. Korst (New York, NY).** The Achilles’ heel of this strategy is that it is hard to predict which tumors will be refractory to IFNγ gamma, and which will upregulate class I with other agents, including retinoids. Also, the exact mechanism behind this upregulation is unclear.